Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents
Aim: This study discloses the synthesis and the antimicrobial and anticancer activities of four molecules of structural basis saccharin-thiadiazolyl (4), saccharin-pyridyl (6, 8), and tetrazole-thiadiazolyl (11). Methods: Antimicrobial properties of the molecules were evaluated by the well-diffusion...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2023-11-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100828/100828.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199576468946944 |
|---|---|
| author | Luís M. T. Frija Bruno E. C. Guerreiro Inês C. C. Costa Vera M. S. Isca Lucília Saraiva Beatriz G. Neves Mariana Magalhães Célia Cabral Maria L. S. Cristiano Patrícia Rijo |
| author_facet | Luís M. T. Frija Bruno E. C. Guerreiro Inês C. C. Costa Vera M. S. Isca Lucília Saraiva Beatriz G. Neves Mariana Magalhães Célia Cabral Maria L. S. Cristiano Patrícia Rijo |
| author_sort | Luís M. T. Frija |
| collection | DOAJ |
| description | Aim: This study discloses the synthesis and the antimicrobial and anticancer activities of four molecules of structural basis saccharin-thiadiazolyl (4), saccharin-pyridyl (6, 8), and tetrazole-thiadiazolyl (11). Methods: Antimicrobial properties of the molecules were evaluated by the well-diffusion method, against Gram-positive bacteria [Staphylococcus aureus American Type Culture Collection (ATCC) 25923, Staphylococcus epidermidis ATCC 12228, Mycobacterium smegmatis ATCC 607], Gram-negative bacteria (Pseudomonas aeruginosa ATCC 27853) and yeast (Saccharomyces cerevisiae ATCC 2601 and Candida albicans ATCC 10231) strains. The anticancer activity of the compounds was assessed through i) proliferation assays for HCT116, MCF-7, and A375 human cell lines [cells were treated with serial dilutions of compounds and the effect on cell propagation was evaluated by sulforhodamine B (SRB) assay]; ii) antiproliferative and cytotoxic assays for glioma-type cell lines A172 (glioblastoma), U87 (brain-likely glioblastoma), and H4 (neuroglioma; cells were treated with diverse concentrations and the cell viability was assessed using a modified Alamar blue® assay). Results: Compound 11 exhibited significant inhibitory activity against S. aureus and S. epidermidis, with the further molecules demonstrating some inhibitory potential against all the tested Gram-positive, Gram-negative, and yeast strains. Similarly, derivative 11 showed an interesting antiproliferative activity against human colon adenocarcinoma (HCT116), human breast adenocarcinoma (MCF-7), and melanoma (A375) cells, with 50% growth inhibition (GI50) values varying from 3.55 µmol/L to 11.5 µmol/L, in the same order of magnitude of those shown by etoposide. Treatment of brain-like glioblastoma cells (U87) with 11, at the concentration of 100 µg/mL, induced a decrease in cell viability by 50% after 48 h and 72 h. Besides, results attained for A172 cells have shown that compound 11 only induces a significant decrease in cell viability upon treatment at 100 µg/mL for 72 h. A divergent observation was recorded for H4 cells, where the treatment with derivative 11 had promoted a significant decrease in cell viability (< 40–60%), even at concentrations as low as 0.39 µg/mL, after 24 h. Conclusions: This investigation reveals the potential of distinct azole-based conjugates, in particular the tetrazole-thiadiazolyl (11) derivative, as scaffolds worth further investigations, in the frame of antimicrobial and antineoplastic chemotherapy. |
| format | Article |
| id | doaj-art-6db59c43d9ae48dfb796d08883a97e60 |
| institution | Kabale University |
| issn | 2836-7677 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | Open Exploration |
| record_format | Article |
| series | Exploration of Drug Science |
| spelling | doaj-art-6db59c43d9ae48dfb796d08883a97e602025-02-08T03:44:56ZengOpen ExplorationExploration of Drug Science2836-76772023-11-011642043410.37349/eds.2023.00028Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agentsLuís M. T. Frija0https://orcid.org/0000-0003-3252-3482Bruno E. C. Guerreiro1Inês C. C. Costa2Vera M. S. Isca3Lucília Saraiva4Beatriz G. Neves5Mariana Magalhães6Célia Cabral7Maria L. S. Cristiano8https://orcid.org/0000-0002-9447-2855Patrícia Rijo9https://orcid.org/0000-0001-7992-8343Institute of Molecular Sciences (IMS), Centro de Química Estrutural (CQE), Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, PortugalCenter of Marine Sciences (CCMAR), Department of Chemistry and Pharmacy (FCT) Gambelas Campus, University of Algarve, P-8005-039 Faro, PortugalCenter of Marine Sciences (CCMAR), Department of Chemistry and Pharmacy (FCT) Gambelas Campus, University of Algarve, P-8005-039 Faro, PortugalCBIOS - Research Center for Health Sciences & Technologies, ULusófona de Humanidades e Tecnologias, 1749-024 Lisboa, Portugal; iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, PortugalLAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, PortugalFaculty of Medicine, Clinic Academic Center of Coimbra (CACC), Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, PortugalFaculty of Medicine, Clinic Academic Center of Coimbra (CACC), Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal; PhD Programme in Experimental Biology and Biomedicine, Institute for Interdisciplinary Research (IIIUC), University of Coimbra, 3030-789 Coimbra, Portugal; Center for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-504 Coimbra, PortugalFaculty of Medicine, Clinic Academic Center of Coimbra (CACC), Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal; Department of Life Sciences, Centre for Functional Ecology, University of Coimbra, 3000-456 Coimbra, PortugalCenter of Marine Sciences (CCMAR), Department of Chemistry and Pharmacy (FCT) Gambelas Campus, University of Algarve, P-8005-039 Faro, PortugalCBIOS - Research Center for Health Sciences & Technologies, ULusófona de Humanidades e Tecnologias, 1749-024 Lisboa, Portugal; iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, PortugalAim: This study discloses the synthesis and the antimicrobial and anticancer activities of four molecules of structural basis saccharin-thiadiazolyl (4), saccharin-pyridyl (6, 8), and tetrazole-thiadiazolyl (11). Methods: Antimicrobial properties of the molecules were evaluated by the well-diffusion method, against Gram-positive bacteria [Staphylococcus aureus American Type Culture Collection (ATCC) 25923, Staphylococcus epidermidis ATCC 12228, Mycobacterium smegmatis ATCC 607], Gram-negative bacteria (Pseudomonas aeruginosa ATCC 27853) and yeast (Saccharomyces cerevisiae ATCC 2601 and Candida albicans ATCC 10231) strains. The anticancer activity of the compounds was assessed through i) proliferation assays for HCT116, MCF-7, and A375 human cell lines [cells were treated with serial dilutions of compounds and the effect on cell propagation was evaluated by sulforhodamine B (SRB) assay]; ii) antiproliferative and cytotoxic assays for glioma-type cell lines A172 (glioblastoma), U87 (brain-likely glioblastoma), and H4 (neuroglioma; cells were treated with diverse concentrations and the cell viability was assessed using a modified Alamar blue® assay). Results: Compound 11 exhibited significant inhibitory activity against S. aureus and S. epidermidis, with the further molecules demonstrating some inhibitory potential against all the tested Gram-positive, Gram-negative, and yeast strains. Similarly, derivative 11 showed an interesting antiproliferative activity against human colon adenocarcinoma (HCT116), human breast adenocarcinoma (MCF-7), and melanoma (A375) cells, with 50% growth inhibition (GI50) values varying from 3.55 µmol/L to 11.5 µmol/L, in the same order of magnitude of those shown by etoposide. Treatment of brain-like glioblastoma cells (U87) with 11, at the concentration of 100 µg/mL, induced a decrease in cell viability by 50% after 48 h and 72 h. Besides, results attained for A172 cells have shown that compound 11 only induces a significant decrease in cell viability upon treatment at 100 µg/mL for 72 h. A divergent observation was recorded for H4 cells, where the treatment with derivative 11 had promoted a significant decrease in cell viability (< 40–60%), even at concentrations as low as 0.39 µg/mL, after 24 h. Conclusions: This investigation reveals the potential of distinct azole-based conjugates, in particular the tetrazole-thiadiazolyl (11) derivative, as scaffolds worth further investigations, in the frame of antimicrobial and antineoplastic chemotherapy.https://www.explorationpub.com/uploads/Article/A100828/100828.pdf134-thiadiazoletetrazolemixed-azolesantimicrobial activityglioblastomacolon adenocarcinomabreast adenocarcinomamelanoma |
| spellingShingle | Luís M. T. Frija Bruno E. C. Guerreiro Inês C. C. Costa Vera M. S. Isca Lucília Saraiva Beatriz G. Neves Mariana Magalhães Célia Cabral Maria L. S. Cristiano Patrícia Rijo Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents Exploration of Drug Science 1 3 4-thiadiazole tetrazole mixed-azoles antimicrobial activity glioblastoma colon adenocarcinoma breast adenocarcinoma melanoma |
| title | Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents |
| title_full | Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents |
| title_fullStr | Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents |
| title_full_unstemmed | Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents |
| title_short | Hybrid azole-based conjugates as upcoming anticancer and antimicrobial agents |
| title_sort | hybrid azole based conjugates as upcoming anticancer and antimicrobial agents |
| topic | 1 3 4-thiadiazole tetrazole mixed-azoles antimicrobial activity glioblastoma colon adenocarcinoma breast adenocarcinoma melanoma |
| url | https://www.explorationpub.com/uploads/Article/A100828/100828.pdf |
| work_keys_str_mv | AT luismtfrija hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT brunoecguerreiro hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT inescccosta hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT veramsisca hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT luciliasaraiva hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT beatrizgneves hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT marianamagalhaes hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT celiacabral hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT marialscristiano hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents AT patriciarijo hybridazolebasedconjugatesasupcominganticancerandantimicrobialagents |